Cellectis S.A. (ALCLS.PA)
EUR 1.45
(4.01%)
EUR 1.45
(4.01%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -92.63 Million USD | 14.92% |
| 2022 | -76.37 Million USD | -4.95% |
| 2021 | -85.43 Million USD | 0.0% |
| 2020 | -43.34 Million USD | 30.85% |
| 2019 | -105.73 Million USD | -17.57% |
| 2018 | -85.9 Million USD | -13.43% |
| 2017 | -100.3 Million USD | -44.85% |
| 2016 | -65.03 Million USD | -123.48% |
| 2015 | -29.22 Million USD | -545.54% |
| 2014 | 4.11 Million USD | -478.62% |
| 2013 | 1.17 Million USD | 104.48% |
| 2012 | -20.75 Million USD | -6.68% |
| 2011 | -24.5 Million USD | -88.77% |
| 2010 | -12.98 Million USD | -26.75% |
| 2009 | -12.25 Million USD | -221.53% |
| 2008 | -3.19 Million USD | 47.69% |
| 2007 | -6.08 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -14.4 Million USD | 67.8% |
| 2024 Q2 | -9.71 Million USD | -31.17% |
| 2023 Q3 | -16.55 Million USD | 30.01% |
| 2023 FY | - USD | 14.92% |
| 2023 Q4 | -44.74 Million USD | -170.25% |
| 2023 Q1 | -18.2 Million USD | -221.55% |
| 2023 Q2 | -23.65 Million USD | -29.99% |
| 2022 Q4 | -5.66 Million USD | 82.93% |
| 2022 Q1 | -26.66 Million USD | 31.92% |
| 2022 FY | - USD | -4.95% |
| 2022 Q2 | -28.96 Million USD | -8.65% |
| 2022 Q3 | -33.16 Million USD | -14.48% |
| 2021 Q3 | -38 Million USD | -11.53% |
| 2021 Q2 | -34.07 Million USD | -226.34% |
| 2021 Q4 | -39.16 Million USD | -3.06% |
| 2021 FY | - USD | 0.0% |
| 2021 Q1 | -10.44 Million USD | 73.34% |
| 2020 FY | - USD | 30.85% |
| 2020 Q1 | 20.04 Million USD | 152.06% |
| 2020 Q2 | -30.88 Million USD | -254.13% |
| 2020 Q3 | -26.78 Million USD | 13.3% |
| 2020 Q4 | -39.16 Million USD | -46.24% |
| 2019 Q2 | -33.43 Million USD | -54.87% |
| 2019 Q3 | -24.92 Million USD | 25.45% |
| 2019 FY | - USD | -17.57% |
| 2019 Q1 | -21.59 Million USD | 26.22% |
| 2019 Q4 | -38.49 Million USD | -54.44% |
| 2018 FY | - USD | -13.43% |
| 2018 Q4 | -29.26 Million USD | -2.92% |
| 2018 Q3 | -28.43 Million USD | -35.01% |
| 2018 Q2 | -21.06 Million USD | 9.13% |
| 2018 Q1 | -23.17 Million USD | 16.52% |
| 2017 Q3 | -25.09 Million USD | -26.04% |
| 2017 Q4 | -27.76 Million USD | -10.64% |
| 2017 FY | - USD | -44.85% |
| 2017 Q2 | -19.9 Million USD | -22.69% |
| 2017 Q1 | -16.22 Million USD | 18.09% |
| 2016 Q2 | -10.64 Million USD | 52.86% |
| 2016 Q4 | -19.81 Million USD | -60.24% |
| 2016 Q3 | -12.36 Million USD | -16.1% |
| 2016 FY | - USD | -123.48% |
| 2016 Q1 | -22.58 Million USD | -1811.82% |
| 2015 Q2 | -13.08 Million USD | -274.18% |
| 2015 FY | - USD | -545.54% |
| 2015 Q1 | -3.49 Million USD | -11691.17% |
| 2015 Q4 | 1.31 Million USD | 109.03% |
| 2015 Q3 | -14.62 Million USD | -11.75% |
| 2014 Q1 | -2.95 Million USD | 40.83% |
| 2014 FY | - USD | -478.62% |
| 2014 Q4 | -29.65 Thousand USD | -105.35% |
| 2014 Q3 | 554.67 Thousand USD | 118.9% |
| 2014 Q2 | -2.93 Million USD | 0.64% |
| 2013 Q3 | -4.9 Million USD | 47.14% |
| 2013 Q4 | -4.99 Million USD | -1.75% |
| 2013 FY | - USD | 104.48% |
| 2013 Q1 | -9.14 Million USD | -72.72% |
| 2013 Q2 | -9.28 Million USD | -1.46% |
| 2012 Q4 | -5.29 Million USD | -11.4% |
| 2012 FY | - USD | -6.68% |
| 2012 Q3 | -4.75 Million USD | 0.0% |
| 2011 FY | - USD | -88.77% |
| 2010 FY | - USD | -26.75% |
| 2009 FY | - USD | -221.53% |
| 2008 FY | - USD | 47.69% |
| 2007 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -2715.684% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 30.457% |
| Adocia SA | -22.73 Million EUR | -307.514% |
| Aelis Farma SA | -6.34 Million EUR | -1359.524% |
| Biophytis S.A. | -13.8 Million EUR | -571.081% |
| Advicenne S.A. | -6.24 Million EUR | -1383.6% |
| genOway Société anonyme | 6.35 Million EUR | 1558.662% |
| IntegraGen SA | -52.5 Thousand EUR | -176339.442% |
| Medesis Pharma S.A. | -3.84 Million EUR | -2309.331% |
| Neovacs S.A. | -8.44 Million EUR | -996.343% |
| NFL Biosciences SA | -4.04 Million EUR | -2187.703% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 127820.943% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -3123.826% |
| Sensorion SA | -22.31 Million EUR | -315.151% |
| Theranexus Société Anonyme | -7.38 Million EUR | -1154.002% |
| TME Pharma N.V. | -5.07 Million EUR | -1726.42% |
| Valbiotis SA | -6.95 Million EUR | -1231.934% |
| TheraVet SA | -517.33 Thousand EUR | -17806.351% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | -389.723% |
| DBV Technologies S.A. | -79.53 Million EUR | -16.478% |
| Genfit S.A. | -28.05 Million EUR | -230.241% |
| GeNeuro SA | -14.31 Million EUR | -547.003% |
| Innate Pharma S.A. | -7.57 Million EUR | -1122.433% |
| Inventiva S.A. | -101.84 Million EUR | 9.045% |
| MaaT Pharma SA | -19.74 Million EUR | -369.281% |
| MedinCell S.A. | -20.04 Million EUR | -362.117% |
| Nanobiotix S.A. | -34.01 Million EUR | -172.307% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | -298.16% |
| Poxel S.A. | -12.17 Million EUR | -660.621% |
| GenSight Biologics S.A. | -21.73 Million EUR | -326.305% |
| Transgene SA | -27.02 Million EUR | -242.792% |
| Valneva SE | -64.51 Million EUR | -43.584% |